Monoclonal antibodies are an exciting advance in the treatment of lymphoma. They are safe and well-tolerated, and exhibit little cross-resistance with conventional chemotherapeutic agents. In indolent lymphomas, antibody therapy has shown useful response rates, both as first-line therapy and in ...
Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia - Part 1: monoclonal antibodies. On- cology (Williston Park) 2015;29:198-203.Siddiqi T,Rosen S T. Novel biologic agents for non-Hodgkin lymphoma and ... JT Sandlund - NIH Public Access 被引量: 0发表: 2009年 ...
Researchers discover antibodies to block common respiratory viruses that put bone marrow and stem cell transplant patients at risk. Experimental Monoclonal Antibodies Show Promise Against Epstein-Barr Virus EBV is associated with certain cancers, including Hodgkin lymphoma, and autoimmune diseases, such as...
Monoclonal antibodies have been developed for a number of cancer targets including Anti-CD20 (B cell lymphoma), Anti-EGFR (multiple targets including head and neck cancer) and anti-VEGFR (Multiple cancer types targeting angiogenesis) (reviewed by Xin et al., 2013). However, the use of ‘...
Bectumomab LymphoScan® Fab' mouse CD22 non-Hodgkin's lymphoma (detection) Belimumab Benlysta®, LymphoStat-B mab human BAFF SLE, non-Hodgkin lymphoma Benralizumab mab humanized CD125 asthma Bertilimumab mab human CCL11 (eotaxin-1) severe allergic disorders ...
A growing number of monoclonal antibodies are being developed for the treatment of malignancies, transplant rejection, autoimmune and other immune disorders; however, they can have severe side effects. Hansel and colleagues consider the mechanisms underl
A disadvantage of bispecific antibodies is that they are ill-suited for heavily treated patients since their activity is critically dependent on the fitness of the patient’s immune cells. In addition, the short half-life requires continuous infusion and has been an issue in some studies. As wi...
Antibodies containing uniform variable regions and thus specific for a single epitope. Originally, monoclonal antibodies were derived from a single B lymphocyte clone. Genetic manipulation now allows genes from multiple sources of B lymphocytes (for example, mouse and human) to be combined. ...
The monoclonal antibodies described in the literature were obtained either from melanoma patients with or without immunisation or by and after immunisation of laboratory animals. However, such efforts for obtaining antibodies which are also effective against melanoma in vivo display great disadvantages. Mur...
The present invention is concerned with novel monoclonal antibodies which define a gylcolipid antigen associated with human non-small cell lung carcinomas ("NSCLC") and certain other human carcinomas.